{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:33Z","timestamp":1791375333598,"version":"4.3.1"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Patients with transfusion\u2010dependent \u03b2\u2010thalassaemia require lifelong, regular red blood cell transfusions for survival; however, frequent blood transfusions are associated with an increased risk of iron overload, transfusion\u2010transmitted disease and alloimmunization, as well as reduced quality of life. Luspatercept, an erythroid maturation agent that promotes late\u2010stage erythroid maturation independently of erythropoietin, has demonstrated efficacy in reducing transfusion burden in patients with transfusion\u2010dependent \u03b2\u2010thalassaemia. In this review, we discuss treatment initiation, ongoing evaluation, dose adjustment and management of adverse events in transfusion\u2010dependent patients with \u03b2\u2010thalassaemia receiving luspatercept, and we provide guidance on how to determine whether patients are deriving clinical benefit.<\/jats:p>","DOI":"10.1111\/bjh.18801","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T21:44:35Z","timestamp":1681163075000},"page":"824-831","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Management of luspatercept therapy in patients with transfusion\u2010dependent \u03b2\u2010thalassaemia"],"prefix":"10.1111","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7640-1244","authenticated-orcid":false,"given":"Sujit","family":"Sheth","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8515-2238","authenticated-orcid":false,"given":"Ali T.","family":"Taher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9878-6029","authenticated-orcid":false,"given":"Thomas D.","family":"Coates","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disease Institute Children's Hospital Los Angeles and USC Keck School of Medicine  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-0655","authenticated-orcid":false,"given":"Antonis","family":"Kattamis","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-6864","authenticated-orcid":false,"given":"Maria Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca\u2019 Granda Policlinico Hospital University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2021838"},{"key":"e_1_2_15_3_1","volume-title":"2021 guidelines for the management of transfusion dependent thalassaemia (TDT)","author":"Cappellini MD","year":"2021"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.02.001"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910182"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-471441"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.265"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25584"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100588"},{"key":"e_1_2_15_10_1","unstructured":"European Medicines Agency.Summary of opinion: Reblozyl\u00ae (luspatercept).2020Available from:https:\/\/www.ema.europa.eu\/en\/documents\/smop\u2010initial\/chmp\u2010summary\u2010positive\u2010opinion\u2010reblozyl_en.pdf"},{"key":"e_1_2_15_11_1","unstructured":"U.S. Food and Drug Administration.FDA approves luspatercept\u2010aamt for anemia in adults with MDS.2020Available from:https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010luspatercept\u2010aamt\u2010anemia\u2010adults\u2010mds"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3512"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511238"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001057"},{"key":"e_1_2_15_15_1","unstructured":"Bristol Myers Squibb.REBLOZYL\u00ae (luspatercept): Highlights of prescribing information.2022Available from:https:\/\/packageinserts.bms.com\/pi\/pi_reblozyl.pdf"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1696"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-163"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167675"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157511"},{"issue":"1","key":"e_1_2_15_20_1","first-page":"108","article-title":"Assessment of response to luspatercept by \u03b2\u2010globin genotype in adult patients with \u03b2\u2010thalassemia in the BELIEVE trial [abstract S295]","volume":"4","author":"Cappellini MD","year":"2020","journal-title":"HemaSphere"},{"issue":"2","key":"e_1_2_15_21_1","first-page":"631","article-title":"Benefit of continuing therapy with luspatercept in patients with \u03b2\u2010thalassemia who do not achieve \u226533% reduction in red blood cell (RBC) transfusion burden (TB) in weeks 13\u201024 in the BELIEVE trial [abstract EP1306]","volume":"5","author":"Piga A","year":"2021","journal-title":"HemaSphere"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122685"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843972.88850.ba"},{"issue":"1","key":"e_1_2_15_24_1","first-page":"5635","article-title":"Treatment patterns and costs of transfusion and chelation in commercially\u2010insured and Medicaid patients with transfusion\u2010dependent \u03b2\u2010thalassemia","volume":"130","author":"Paramore C","year":"2017","journal-title":"Blood"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3959-2"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119864083"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10111436"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000848928.08455.02"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2048065"},{"key":"e_1_2_15_30_1","unstructured":"ClinicalTrials.gov.A study to determine the efficacy and safety of luspatercept in adults with non\u2010transfusion dependent beta (\u03b2)\u2010thalassemia (BEYOND).2021Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03342404"},{"key":"e_1_2_15_31_1","unstructured":"ClinicalTrials.gov.A study to evaluate long\u2010term safety in participants who have participated in other luspatercept (ACE\u2010536) clinical trials.2023Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04064060"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029334"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18470"},{"issue":"5","key":"e_1_2_15_34_1","article-title":"Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia","volume":"5","author":"Fortin PM","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"e_1_2_15_35_1","first-page":"254","article-title":"Medication compliance research: still so far to go","volume":"3","author":"Wertheimer A","year":"2003","journal-title":"J Appl Res Clin Exp Ther"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:06:06Z","timestamp":1713225966000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/bjh.18801"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18801","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"2022-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}